Intellia Therapeutics reported that the first 10 patients with hereditary angioedema who received a CRISPR-based treatment experienced a 98% reduction in swelling attacks, with one patient remaining attack-free for 26 months. Two patients who used to have frequent attacks have now gone over 20 months without any episodes. No patient experienced an attack in the last 11 months of follow-up, and all side effects were mild. These positive results were presented at the European Academy of Allergy and Clinical Immunology Congress. The data suggests that this CRISPR-based treatment shows promising outcomes for patients with hereditary angioedema.
Source link
Intellia reports positive results for its CRISPR-based treatment
